Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBV-specific T-cells for EBV-associated Malignancies
NCT03988582Phase 2Withdrawn
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2019
- Primary completion
- Jun 2020
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Native Immune Cells
01
Overview
Phase 2, open-label trial of baltaleucel-T in Epstein-Barr virus associated lymphoma, Epstein-Barr virus-associated malignancy, Hodgkin lymphoma (HL) and 5 more (3 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Best Overall Response Rate at 6 months. Planned start Jun 2019; status: withdrawn.
02
Drugs
baltaleucel-T
03
Conditions
Epstein-Barr virus associated lymphomaEpstein-Barr virus-associated malignancyHodgkin lymphoma (HL)nasopharyngeal carcinoma (NPC)Epstein–Barr virus-associated gastric cancer (EBVaGC)
Beyond the preview
Go deeper on NCT03988582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03988582.